

CONTACT: Mark Brager
202-434-7244
mbrager@advamed.org



AdvaMed

Advanced Medical Technology Association

News

FOR IMMEDIATE RELEASE

June 19, 2012

AdvaMed Supports Final Medical Device User Fee Legislation

WASHINGTON, D.C. – David Nexon, senior executive vice president for the Advanced Medical Technology Association (AdvaMed), issued the following statement today following release of legislation agreed to by the House and Senate to reauthorize the Medical Device User Fee Act:

“AdvaMed commends the House and Senate for their work in expeditiously reconciling the differences between the two chambers’ versions of FDA user fee legislation. We support the compromise package that has resulted and urge lawmakers to take the next step and approve the final legislative package so it can be sent to the President for his signature as soon as possible.

“We would like thank House Energy and Commerce Committee Chairman Fred Upton (R-Mich.) and Ranking Member Henry Waxman (D-Calif.) and Senate HELP Committee Chair Tom Harkin (D-Iowa) and Ranking Member Michael Enzi (R-Wyo.) for their hard work and commitment in moving this legislation forward. Under their leadership, the user fee reauthorization legislation garnered strong bipartisan support in both the House and Senate. This support reflects the importance of this vital legislation to American patients, the FDA and the medical technology industry.

“The U.S. medical technology industry provides life-changing treatments and cures to millions of patients worldwide. Furthermore, we are a strong contributor to the U.S. economy, responsible for creating more than two million high-paying jobs across the country. The user fee agreement reached between FDA and industry and implemented by this legislation is a potential game-changer that could help accelerate the development and approval of safe and effective treatments and diagnostics.

“Through a combination of groundbreaking accountability and transparency measures and enhanced FDA resources, the user fee agreement has the potential to increase the predictability, consistency and efficiency of FDA’s decision-making, while maintaining the agency’s stringent product approval standards.

“Put simply, this legislation is good for FDA; it is good for industry; and most of all, it is good for American patients.”

###

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.